RESUMO
The present study was aimed at the evaluation of neuroprotective ability of methanolic extract of Trianthema decandra (METD) against hyperglycemia-related cognitive impairment in rats. The extract of T. decandra was standardized by TLC and HPTLC methods. To verify the identity and purity of isolated compounds, they were segregated and characterized using various techniques, including UV-visible spectrophotometry, FT-IR, H-NMR, and Mass spectroscopy. α-Amylase and α-glucosidase inhibition property of the extracts were assessed in-vitro. The screening of the neuroprotective effects of METD in hyperglycemic rats was done utilizing Morri's water (MWM) and elevated plus maze (EPM) model, as well as acetylcholinesterase (AChE) activity. The extracts of Trianthema decandra and its chemical constituents, namely quercetin and phytol, demonstrated a significant protective effect on enzymes like α-amylase and α-glucosidase. Methanol and hydroalcoholic extracts have shown the strongest inhibitory activity followed by chloroform extract. Quercetin and phytol were associated with the methanolic and chloroform extracts which were identified using TLC and HPTLC techniques. During the thirty days of the study, the induction of diabetes in the rats exhibited persistent hyperglycemia, hyperlipidemia, higher escape latency during training trials and reduced time spent in target quadrant in probe trial in Morris water maze test, and increased escape latency in EPM task. Regimen of METD (200 and 400 mg/kg) in the diabetic rats reduced the glucose levels in blood, lipid, and liver profile and showed positive results on Morri's water and elevated plus maze tasks. During the investigation, it was determined that Trianthema decandra extracts and the chemical constituent's quercetin and phytol in it had anti-diabetic and neuroprotective activities.
RESUMO
Diabetic wound (DW) is a major complication of diabetes mellitus that often ends up with amputation of the concerned organ. The current therapies for DW include glucose regulation, wound debridement, pressure off-loading, surgeries, hyperbaric oxygen therapy, maggot therapy, and so on. However, the majority are not meeting all the prerequisites of DW because of extensive pathology and cost associated with the strategies. So, to overcome the problems related to the existing conventional therapies, we hypothesized to repurpose the current drugs, which can target a receptor having a considerable role in the progression of DW might be beneficial. One major challenge of DW is multifaceted pathophysiology includes prolonged inflammation, increased infections, decreased cell proliferation, and migration. Many shreds of evidence disclosed that inhibition of GSK-3ß could result in reduced inflammation and infection, followed by increased cell proliferation and migration. Thus, we selected the GSK-3ß receptor as a ubiquitous target for the treatment of multifactorial pathophysiology of DW. In the current hypothetical study, we investigated the use of rosiglitazone as a therapeutic modulator against the GSK-3ß receptor. To validate our hypothesis, computational studies such as molecular docking and MMGBSA were performed. From the in silico methods, it is evident that rosiglitazone established a higher binding affinity against the selected receptor. Further, the Molecular Dynamic simulation study has revealed stable interaction of rosiglitazone against GSK-3ß complex. Thus, rosiglitazone might be a drug of choice in the therapeutic management of DW.
